Tim Smith

Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.

These data suggest brodalumab's safety profile is consistent with findings from long-term clinical trials, with no new occurrences of suicide and a low rate of fungal infection.

This interview from Fall Clinical featured a discussion of new findings on upadacitinib (Rinvoq) for patients with atopic dermatitis.

This conference review highlights several of the most notable stories and recent data covered by HCPLive at the Fall Clinical Dermatology Conference.

This interview with Kraft features a discussion regarding her team's new data from the BATURA study on albuterol for patients' asthma exacerbations.

In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.

In this geospatial analysis, findings indicate that geographic regions with more tanning bed facilities tend to report higher melanoma rates.

The acceptance of the investigational gene therapy's Biologics License Application was announced, with the treatment designed for recessive dystrophic epidermolysis bullosa.

A new analysis highlights the seasonal patterns of airborne fungal spores that can be found in the central region of England, with a calendar developed to this same end.

In this analysis, the benefits of 2’-FL for mothers’ offspring with regard to allergies were highlighted by investigators.